======= PPP3CA =======
== Gene Information ==
* **Official Symbol**: PPP3CA
* **Official Name**: protein phosphatase 3 catalytic subunit alpha
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=5530|5530]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q08209|Q08209]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PPP3CA&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PPP3CA|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/114105|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Calcium-dependent, calmodulin-stimulated protein phosphatase. Many of the substrates contain a PxIxIT motif. This subunit may have a role in the calmodulin activation of calcineurin. Dephosphorylates DNM1L, HSPB1 and SSH1. {ECO:0000269|PubMed:15671020, ECO:0000269|PubMed:17498738, ECO:0000269|PubMed:18838687}.
|Metallophos|
|positive regulation of cardiac muscle adaptation|
|positive regulation of cardiac muscle hypertrophy in response to stress|
|positive regulation of connective tissue replacement|
|regulation of connective tissue replacement|
|calcineurin complex|
|calmodulin-dependent protein phosphatase activity|
|positive regulation of muscle adaptation|
|regulation of cardiac muscle adaptation|
|regulation of cardiac muscle hypertrophy in response to stress|
|negative regulation of chromatin binding|
|transition between fast and slow fiber|
|slit diaphragm|
|negative regulation of production of miRNAs involved in gene silencing by miRNA|
|calcineurin-NFAT signaling cascade|
|negative regulation of gene silencing by miRNA|
|muscle hypertrophy in response to stress|
|cardiac muscle adaptation|
|cardiac muscle hypertrophy in response to stress|
|regulation of skeletal muscle adaptation|
|calcineurin-mediated signaling|
|peptidyl-serine dephosphorylation|
|negative regulation of posttranscriptional gene silencing|
|postsynaptic modulation of chemical synaptic transmission|
|negative regulation of dendrite morphogenesis|
|negative regulation of gene silencing by RNA|
|regulation of production of miRNAs involved in gene silencing by miRNA|
|regulation of production of small RNA involved in gene silencing by RNA|
|regulation of chromatin binding|
|inositol phosphate-mediated signaling|
|skeletal muscle fiber development|
|cyclosporin A binding|
|striated muscle adaptation|
|myotube cell development|
|cardiac muscle hypertrophy|
|negative regulation of dendrite development|
|striated muscle hypertrophy|
|positive regulation of cardiac muscle hypertrophy|
|positive regulation of tissue remodeling|
|positive regulation of muscle hypertrophy|
|response to amphetamine|
|muscle adaptation|
|muscle hypertrophy|
|skeletal muscle tissue regeneration|
|negative regulation of gene silencing|
|Wnt signaling pathway, calcium modulating pathway|
|negative regulation of insulin secretion|
|negative regulation of peptide hormone secretion|
|response to amine|
|response to bronchodilator|
|cytoplasmic side of plasma membrane|
|regulation of cardiac muscle hypertrophy|
|myotube differentiation|
|drug binding|
|muscle fiber development|
|regulation of muscle hypertrophy|
|excitatory postsynaptic potential|
|negative regulation of hormone secretion|
|tissue regeneration|
|protein serine/threonine phosphatase activity|
|chemical synaptic transmission, postsynaptic|
|multicellular organismal response to stress|
|cellular response to glucose stimulus|
|cellular response to hexose stimulus|
|cellular response to monosaccharide stimulus|
|regulation of tissue remodeling|
|cellular response to carbohydrate stimulus|
|Schaffer collateral - CA1 synapse|
|regulation of muscle adaptation|
|regulation of gene silencing by miRNA|
|cellular glucose homeostasis|
|regulation of gene silencing by RNA|
|regulation of posttranscriptional gene silencing|
|regulation of dendrite morphogenesis|
|protein import into nucleus|
|negative regulation of cell morphogenesis involved in differentiation|
|sarcolemma|
|regulation of postsynaptic membrane potential|
|positive regulation of endocytosis|
|import into nucleus|
|G1/S transition of mitotic cell cycle|
|cell cycle G1/S phase transition|
|skeletal muscle tissue development|
|regulation of gene silencing|
|negative regulation of protein secretion|
|Z disc|
|skeletal muscle organ development|
|non-canonical Wnt signaling pathway|
|striated muscle cell development|
|response to glucose|
|negative regulation of peptide secretion|
|protein import|
|response to hexose|
|calcium-mediated signaling|
|muscle cell development|
|dendritic spine|
|response to monosaccharide|
|regulation of dendrite development|
|response to calcium ion|
|negative regulation of neuron projection development|
|regeneration|
|protein dimerization activity|
|protein localization to nucleus|
|negative regulation of binding|
|response to carbohydrate|
|Fc-epsilon receptor signaling pathway|
|regulation of insulin secretion|
|negative regulation of protein transport|
|negative regulation of cell projection organization|
|glucose homeostasis|
|negative regulation of establishment of protein localization|
|carbohydrate homeostasis|
|striated muscle cell differentiation|
|calmodulin binding|
|negative regulation of secretion by cell|
|regulation of endocytosis|
|regulation of peptide hormone secretion|
|protein dephosphorylation|
|negative regulation of neuron differentiation|
|negative regulation of secretion|
|T cell activation|
|regulation of muscle system process|
|Fc receptor signaling pathway|
|muscle cell differentiation|
|calcium ion transport|
|positive regulation of DNA-binding transcription factor activity|
|nucleocytoplasmic transport|
|nuclear transport|
|regulation of hormone secretion|
|mitotic cell cycle phase transition|
|aging|
|cell cycle phase transition|
|striated muscle tissue development|
|negative regulation of neurogenesis|
|divalent metal ion transport|
|muscle organ development|
|muscle tissue development|
|muscle system process|
|response to xenobiotic stimulus|
|divalent inorganic cation transport|
|regulation of cell morphogenesis involved in differentiation|
|dephosphorylation|
|negative regulation of nervous system development|
|negative regulation of cell development|
|second-messenger-mediated signaling|
|glutamatergic synapse|
|enzyme binding|
|Wnt signaling pathway|
|cell-cell signaling by wnt|
|response to metal ion|
|regulation of binding|
|lymphocyte activation|
|developmental growth|
|growth|
|cellular response to drug|
|positive regulation of cell adhesion|
|chemical synaptic transmission|
|anterograde trans-synaptic signaling|
|cell surface receptor signaling pathway involved in cell-cell signaling|
|regulation of DNA-binding transcription factor activity|
|regulation of membrane potential|
|establishment of protein localization to organelle|
|trans-synaptic signaling|
|modulation of chemical synaptic transmission|
|regulation of trans-synaptic signaling|
|synaptic signaling|
|regulation of protein secretion|
|muscle structure development|
|wound healing|
|immune response-regulating cell surface receptor signaling pathway|
|negative regulation of transport|
|protein heterodimerization activity|
|regulation of cell morphogenesis|
|regulation of peptide secretion|
|regulation of neuron projection development|
|positive regulation of cell migration|
|response to toxic substance|
|positive regulation of cell motility|
|response to inorganic substance|
|regulation of hormone levels|
|positive regulation of cellular component movement|
|regulation of vesicle-mediated transport|
|positive regulation of locomotion|
|response to wounding|
|regulation of system process|
|immune response-regulating signaling pathway|
|mitotic cell cycle process|
|metal ion transport|
|regulation of neuron differentiation|
|regulation of cell adhesion|
|mitotic cell cycle|
|regulation of plasma membrane bounded cell projection organization|
|negative regulation of cellular component organization|
|regulation of protein transport|
|regulation of cell projection organization|
|negative regulation of cell differentiation|
|calcium ion binding|
|protein localization to organelle|
|regulation of peptide transport|
|brain development|
|cellular chemical homeostasis|
|regulation of establishment of protein localization|
|regulation of secretion by cell|
|head development|
|regulation of secretion|
|regulation of neurogenesis|
|cation transport|
|regulation of cell migration|
|cellular homeostasis|
|regulation of cell motility|
|regulation of nervous system development|
|leukocyte activation|
|regulation of cell development|
|negative regulation of developmental process|
|central nervous system development|
|regulation of locomotion|
|positive regulation of transport|
|intracellular protein transport|
|regulation of cellular component movement|
|cell cycle process|
|response to organonitrogen compound|
|response to drug|
|regulation of protein localization|
|cellular response to oxygen-containing compound|
|regulation of anatomical structure morphogenesis|
|cell activation|
|response to nitrogen compound|
|chemical homeostasis|
|cell-cell signaling|
|negative regulation of molecular function|
|regulation of immune response|
|negative regulation of multicellular organismal process|
|positive regulation of cellular component organization|
|positive regulation of transcription by RNA polymerase II|
|mitochondrion|
|negative regulation of RNA metabolic process|
|cell cycle|
|negative regulation of cell communication|
|negative regulation of signaling|
|ion transport|
|nervous system process|
|negative regulation of nucleobase-containing compound metabolic process|
|regulation of response to stress|
|protein transport|
|intracellular transport|
|generation of neurons|
|peptide transport|
|positive regulation of transcription, DNA-templated|
|response to oxygen-containing compound|
|amide transport|
|cellular protein localization|
|cellular macromolecule localization|
|establishment of protein localization|
|neurogenesis|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|homeostatic process|
|cell development|
|regulation of immune system process|
|intracellular signal transduction|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|positive regulation of multicellular organismal process|
|tissue development|
|positive regulation of molecular function|
|regulation of cell differentiation|
|establishment of localization in cell|
|nitrogen compound transport|
|regulation of transport|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|system process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-1.85|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-1.84|
|[[:results:exp77|Prochlorperazine 5.2μM R02 exp77]]|1.7|
|[[:results:exp230|Epigallocatechin gallate 20μM R05 exp230]]|1.71|
|[[:results:exp81|Selumetinib 20μM R02 exp81]]|1.73|
|[[:results:exp524|Staurosporine 0.02μM R08 exp524]]|1.73|
|[[:results:exp189|Temozolomide 200μM R04 exp189]]|1.73|
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|1.81|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|1.82|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|1.82|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|1.82|
|[[:results:exp285|GW501516 25μM R06 exp285]]|1.9|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|1.9|
|[[:results:exp300|VE-822 0.04μM R06 exp300]]|1.93|
|[[:results:exp115|A-366 10μM R03 exp115]]|1.96|
|[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|1.98|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|2.07|
|[[:results:exp514|Phorbol-12-myristate-13-acetate 0.57μM R08 exp514]]|2.13|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|2.14|
|[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|2.2|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|2.23|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|2.25|
|[[:results:exp447|Amiloride 100μM R08 exp447]]|2.41|
|[[:results:exp59|UMK57 1μM R01 exp59]]|2.41|
|[[:results:exp269|Bisphenol A 100μM R06 exp269]]|2.43|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|2.88|
|[[:results:exp82|Torin1 0.08μM R02 exp82]]|2.92|
|[[:results:exp215|Colchicine 0.009μM R05 exp215]]|3.09|
|[[:results:exp306|Rapamycin 2μM R07 exp306]]|3.13|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|3.16|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|3.2|
|[[:results:exp71|KU-0063794 3.8μM R02 exp71]]|3.8|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|3.87|
|[[:results:exp70|INK128 0.2μM R02 exp70]]|4.22|
^Gene^Correlation^
|[[:human genes:p:ppp3r1|PPP3R1]]|0.704|
|[[:human genes:n:nfatc3|NFATC3]]|0.632|
|[[:human genes:i:itpr1|ITPR1]]|0.575|
|[[:human genes:g:gna15|GNA15]]|0.523|
|[[:human genes:n:nckap1l|NCKAP1L]]|0.464|
|[[:human genes:r:ruvbl2|RUVBL2]]|0.438|
|[[:human genes:l:lpar5|LPAR5]]|0.412|
|[[:human genes:k:klhl12|KLHL12]]|0.407|
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 12715
* **Expression level (log2 read counts)**: 5.39
{{:chemogenomics:nalm6 dist.png?nolink |}}